These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 16436779)
1. Cabergoline and mitral regurgitation. Delgrange E N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779 [No Abstract] [Full Text] [Related]
2. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372 [TBL] [Abstract][Full Text] [Related]
8. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454 [TBL] [Abstract][Full Text] [Related]
9. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Sherlock M; Toogood AA; Steeds R Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419 [No Abstract] [Full Text] [Related]
10. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups]. Lökk J Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806 [No Abstract] [Full Text] [Related]
11. [Mitral valve replacement for cabergoline-related severe mitral regurgitation]. Hanada T; Shimizu K; Murakami R; Ota T; Okada S; Inoue S; Hiroe K; Higaki Y; Oda T Kyobu Geka; 2007 Oct; 60(11):1018-21. PubMed ID: 17926907 [TBL] [Abstract][Full Text] [Related]
12. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks? Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763 [No Abstract] [Full Text] [Related]
13. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314 [TBL] [Abstract][Full Text] [Related]
14. Cabergoline and the risk of valvular lesions in endocrine disease. Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Ozer N; Yorgun H; Canpolat U; Elibol B Anadolu Kardiyol Derg; 2014 Mar; 14(2):121-7. PubMed ID: 24449623 [TBL] [Abstract][Full Text] [Related]